Product news

Share this article:
Genzyme announced an FDA marketing approval for Mozobil (plerixafor injection), a drug to be used in combination with a granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The product also received an orphan drug designation. 
 
Following an FDA safety alert on oral sodium phosphates (OSP), C.B. Fleet has announced a voluntary recall of over-the-counter products Fleet Phospho-soda and Fleet Phospho-soda EZ-Prep Bowel Cleansing System. The FDA recommended that these products not be used for bowel cleansing. Two prescription OSPs manufactured by Salix Pharmaceuticals, Visicol and OsmoPrep, were given box warnings related to the risk of acute kidney injury.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.